HIV protease mutations associated with amprenavir resistance during salvage therapy: Importance of I54M

Journal of Clinical Virology

Volumn 30, Issue 1, 2004, Pages 62-67

  Murphy, Melissa D ^a,b   Marousek, Gail I ^a   Chou, Sunwen ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amprenavir; HIV; Resistance mutations

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD;

AMINO ACID SUBSTITUTION; CARBAMATES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION, MISSENSE; PHENOTYPE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SULFONAMIDES; VIRAL LOAD;

EID: 1842608902     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2003.08.013     Document Type: Article

References (12)

1. Chou S, McMillan G, Strausbaugh L, Marousek G. Amprenavir resistance associated with emergence of HIV protease mutation I54M. In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ont., Canada, September 2000 [abstract 1266].
2. Falloon J., Piscitelli S., Vogel S., Sadler B., Mitsuya H., Kavlick M.et al. Combination therapy with amprenavir, abacavir and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:2000;313-318.
3. Falloon J., Ait-Khaled M., Thomas D., Brosgart C.L., Eron J.J., Feinberg J.et al. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS. 16:2002;387-396.
4. Kim E.E., Baker C.T., Dwyer M.D.et al. Crystal-structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1995;1181-1182.
5. Maguire M., Shortino D., Klein A., Harris W., Manohitharajah V., Tisdale M.et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:2002;731-738.
6. Ohtaka H., Velazquez-Campoy A., Xie D., Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11:2002;1908-1916.
7. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B.et al. In vitro selection and characterization of human immunodeficiency type 1 (HIV-1) isolates with reduced sensistivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:1995;5228-5235.
8. Paulsen D., Liao Q., Fusco G., St Clair M., Shaefer M., Ross L. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res. Hum. Retroviruses. 18:2002;1011-1019.
9. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W. et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:2000;920-928.
10. Race E., Dam E., Obry V., Paulous S., Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. 13:1999;2061-2068.
11. Tisdale M, Myers RE, Ait-Khaled M, Snowden WA. HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir. In: Proceedings of the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 1999 [abstract 118].
12. Xu R, Andrews W, Spaltenstein A, Danger D, Dallas W, Carter L, et al. Molecular mechanism of I50V HIV-1 protease resistance and cross-resistance to protease inhibitors. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002 [poster 563T].